Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.

@article{Barnett2012LinagliptinMI,
  title={Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.},
  author={Anthony Barnett and Sanjay R. Patel and Roy Harper and Robert Toorawa and Sandra Thiemann and Maximilian von Eynatten and H. J. Woerle},
  journal={Diabetes, obesity & metabolism},
  year={2012},
  volume={14 12},
  pages={1145-54}
}
AIMS To investigate the efficacy and safety of linagliptin, a dipeptidyl peptidase-4 inhibitor, in type 2 diabetes mellitus (T2DM) patients for whom metformin was inappropriate. METHODS This 1-year double-blind study (ClinicalTrials.gov, NCT00740051) enrolled T2DM patients with inadequate glycaemic control, treatment-naïve [glycated haemoglobin (HbA1c) 7.0-10.0%] or previously treated with one oral antidiabetes drug (HbA1c 6.5-9.0% before washout), ineligible for metformin because of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Similar Papers

Loading similar papers…